Neogen Corporation

Fundamentals8.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Positive EBITDA
  • Improved liquidity
  • Intangible concentration

AI
AI Summary

6.0

NEOG's investment thesis has shifted from acquisitive growth to a high‑execution turnaround where the stock will only re-rate if management converts recent positive quarterly EBITDA and FCF into several consecutive, sustainable quarters of cash generation while materially reducing net debt—critical catalysts are a successful PetriFilm production transfer (to stop scrap/write-offs) and timely deleveraging using divestiture proceeds. If those operational fixes and working‑capital improvements fail or cash generation falters, the company remains exposed to impairment, interest‑coverage stress, and further downside; investors should watch consecutive quarters of EBITDA/FCF and debt reduction as go/no‑go signals.

TurnaroundOpportunity
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Positive EBITDA
  • Improved liquidity
  • Intangible concentration

NEOG's latest quarter shows clear operational stabilization with positive EBITDA, improving liquidity and free cash flow, but remains constrained by prior-year scale losses, large intangibles and mixed solvency that weigh on valuation.

Stabilizing
LegacyRisks

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Downtrend momentum
  • Support turned resistance
  • Mean-reversion risk

NEOG is in a clear downtrend after dropping ~26% last month from $11.33 to $8.36, breaking $9.65–$9.70 support (now potential resistance) and leaving downside risk until price reclaims $9.70+ for confirmation.

bearish
watch
Support Level: $9.65–$9.70
Resistance Level: $11.23–$11.33

Rapid ~26% decline from $11.33 to $8.36 last month, raising short-term bounce potential

Sentiment & News

6.0

Key News Insights:

  • Genomics sale
  • Mixed sentiment
  • Active repositioning

Neogen is simplifying its portfolio by selling its global genomics unit to Zoetis for $160M, prompting mixed analyst sentiment and active institutional repositioning.

Repositioning
Divestiture

The divestiture narrows Neogen's focus and should prompt near-term revaluation as investors and analysts reassess growth and margin prospects